Bayer Corporation v. Mary Reed

Mississippi Supreme Court·Decided September 21, 2004·No. 2004-IA-01968-SCT·Published

Opinion

IN THE SUPREME COURT OF MISSISSIPPI NO. 2004-IA-01968-SCT

BAYER CORPORATION v. MARY REED

DATE OF JUDGMENT: 09/21/2004 TRIAL JUDGE: HON. JANNIE M. LEWIS COURT FROM WHICH APPEALED: HOLMES COUNTY CIRCUIT COURT ATTORNEYS FOR APPELLANT: CAROLYN ALLEEN McLAIN GERALD H. JACKS

WILLIAM F. GOODMAN, III

ROBERT L. JOHNSON, III

ATTORNEYS FOR APPELLEE: RICHARD JOSEPH PLEZIA EDWARD BLACKMON, JR.

PATRICK MALOUF

ROBERT FARLEY WILKINS

NATURE OF THE CASE: CIVIL - PERSONAL INJURY DISPOSITION: AFFIRMED AND REMANDED - 06/29/2006

MOTION FOR REHEARING FILED: MANDATE ISSUED:

EN BANC.

WALLER, PRESIDING JUSTICE, FOR THE COURT:

¶1. This interlocutory appeal arises from the Holmes County Circuit Court’s denial of Bayer Corporation’s motion for a change of venue. Bayer asserts that the circuit court abused its discretion in denying its motion for change of venue because it would experience substantial prejudice by way of citizen bias and pretrial publicity if the jury venire was composed of citizens of Holmes County. We find that the circuit court was correct in

denying Bayer Corporation’s motion for change of venue, but not for the reasons stated in the order. A review of the merits of the motion for change of venue shows that Bayer did not provide sufficient evidence of bias, prejudice or undue influence to support its allegations.

FACTS

¶2. Bayer is the maker of the prescription medication Baycol (cerivastatin), which was prescribed by physicians to help lower the lipid levels of people suffering from high cholesterol. Prior to mass production, Baycol was approved by the United States Food and Drug Administration. Its package insert described possible side-effects, chemical interactions and dosage warnings for physicians. Specifically, the package insert warned of the possibility of myopathy1 when Baycol was used in conjunction with another drug, gemfibrozil, or when the user is started at the highest dosage of .8 mg rather than a gradual step-up from a lower starting value. Despite these warnings, Bayer received reports of a severe type of myopathy referred to as rhabdomyolysis.2 Thereafter, Bayer voluntarily withdrew Baycol from the market in August 2001.

1 A disease of muscle or muscle tissue.

2 Rhabdomyolysis is the breakdown of muscle fibers resulting in the release of muscle fiber contents into the circulation. Some of these are toxic to the kidney and frequently result in kidney damage.

¶3. Mary Reed 3 had a history of health problems including a four-year period, from 1996- 2000, in which she was largely incapacitated and bedridden due to pain and fatigue in her hands and arms. Unrelated to these problems, Reed began taking Baycol in March 2000 and continued taking it for seven months. Reed gives no reason for the discontinuance of the drug other than “she just ran out of her medicine and . . . didn’t have it refilled.” She now attributes pain in her arms, hands and shoulders to myopathy related to her use of Baycol. However, at the time she used the medication, she did not complain of any Baycol-related injuries to her doctor, John Downer, M. D., or her nurse practitioner.

¶4. Reed filed suit on September 9, 2002, against Bayer after seeing an attorney advertisement on television soliciting for Baycol users. It was not until after her lawsuit was filed that her new physician, Calvin Ramsey, M. D., diagnosed her with a Baycol-related injury.

¶5. After the circuit court denied Bayer’s motion for change of venue, Bayer filed a petition seeking permission to file an interlocutory appeal, which petition was granted by this Court. See M.R.A.P. 5.

DISCUSSION

¶6. The decision to deny or grant a motion for a change of venue lies within the discretion of the trial court. Beech v. Leaf River Forest Prods., Inc., 691 So. 2d 446, 448 (Miss. 1997).

3

Originally, there were two other plaintiffs, Aubrey Dean and Willie McCurdy. Their claims were voluntarily severed and transferred to other jurisdictions. Also Reed initially maintained a claim against SmithKline Beecham Corporation d/b/a GlaxoSmithKline, which was dismissed with prejudice.

We will not overturn that decision unless the trial court abuses its discretion. Id. It is the plaintiff’s prerogative to decide where, among permissible venues, to sue the defendant. Forrest County Gen. Hosp. v. Conway, 700 So. 2d 324, 326 (Miss. 1997). Therefore, absent weighty reasons, a plaintiff’s choice of forum should not be disturbed. Purdue Pharma, L.P. v. Estate of Heffner, 904 So. 2d 100, 102 (Miss. 2004). That being said, one of the basic tenets in our jurisprudence is “no matter how guilty one may be, no matter how atrocious his crime, nor how certain his doom, when brought to trial anywhere he shall, nevertheless, have the same fair and impartial trial accorded to the most innocent defendant.” King v. Kelly, 243 Miss. 160, 173, 137 So. 2d 808, 813 (1962) (quoting Tennison v. State, 79 Miss. 708, 31 So. 421, 422 (1902)). Although “the decisions on change of venue deal primarily and predominantly with criminal cases, a person is also entitled to a fair and impartial trial in a civil case.” King, 137 So. 2d at 813.

I. WHETHER THE CIVIL CHANGE OF VENUE STATUTE REQUIRES AN AFFIDAVIT.

¶7. After Bayer presented evidence of numerous legal advertisements and pre-trial publicity (both in newspapers and on television), allegedly producing a litigious environment in Holmes County, the circuit court denied Bayer’s motion for change of venue, stating as follows:

Next is [Bayer’s] motion for change of venue. [The]

Court has read the motion, as well as the response, and that motion is denied. [The] Court does not find sufficient evidence – there is no affidavit from any Holmes County resident that

says [Bayer] could not receive a fair and impartial trial in Holmes County. That motion is denied.

Even though the circuit court denied the motion on the general basis of insufficient evidence, the circuit court specifically faulted Bayer for failing to present a Holmes County citizen’s affidavit.

¶8. Bayer correctly asserts that the circuit court, by requiring an affidavit from a Holmes County resident, has imposed an additional burden not required under Mississippi law. Miss. Code Ann. § 11-11-51 (Rev. 2004) does not require such an affidavit. When a statute is unambiguous it is inappropriate for a court to add or take anything away from it. Wallace v. Raleigh, 815 So. 2d 1203, 1208 (Miss. 2002). The statute, which has not been amended since 1942, is clear and unambiguous. Our recent decisions regarding change of venue in a civil action do not require such an affidavit. See Janssen Pharmaceutica, Inc. v. Bailey, 878 So. 2d 31, 49 (Miss. 2004); Beech v. Leaf River Forest Prods., Inc., 691 So. 2d 446, 450 (Miss. 1997) (finding change of venue reasonable because of pretrial publicity and numerous similar claims filed in the same county; but not requiring an affidavit). The circuit court therefore erred when it required Bayer’s motion for change of venue to be accompanied by an affidavit from a citizen of the county in which suit is filed stating that a defendant cannot receive a fair trial in that county. However, this error is harmless inasmuch as we affirm the denial of the motion on different grounds.

II. CHANGE OF VENUE BASED ON UNDUE INFLUENCE OR PREJUDICE.

¶9. Bayer contends that it would be prejudiced in a Holmes County trial because (1) Calvin Ramsey, M. D., “a prominent physician with an active practice [with over 2000 patients] in Holmes County,” would be testifying on behalf of the plaintiff; (2) dozens of plaintiffs reside in Holmes County; (3) more than 135 product liability/pharmaceutical tort cases with more than 2200 plaintiffs have been filed in Holmes County in the past six years; (4) significant publicity including attorney advertisements in the county newspaper regarding lawsuits associated with prescription drugs which has permeated Holmes County; and (5) a local hostility toward business.

Free access — add to your briefcase to read the full text and ask questions with AI

Bayer Corporation v. Mary Reed, (Mich. 2004).

Bayer Corporation v. Mary Reed (Bayer Corporation v. Mary Reed) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Wallace v. Town of Raleigh
815 So. 2d 1203 (Mississippi Supreme Court, 2002)
Janssen Pharmaceutica, Inc. v. Bailey
878 So. 2d 31 (Mississippi Supreme Court, 2004)
Purdue Pharma, LP v. Estate of Heffner
904 So. 2d 100 (Mississippi Supreme Court, 2004)
Forrest County General Hosp. v. Conway
700 So. 2d 324 (Mississippi Supreme Court, 1997)
Beech v. Leaf River Forest Products, Inc.
691 So. 2d 446 (Mississippi Supreme Court, 1997)
Flight Line, Inc. v. Tanksley
608 So. 2d 1149 (Mississippi Supreme Court, 1992)
KING & USF & G. CO. v. Kelly
137 So. 2d 808 (Mississippi Supreme Court, 1962)
RE/Max Real Estate Partners v. Lindsley
840 So. 2d 709 (Mississippi Supreme Court, 2003)
Tennison v. State
79 Miss. 708 (Mississippi Supreme Court, 1901)